Page 15 - Patrick Wingrove News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AstraZeneca on Friday said it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus, which was approved in July to prevent the disease in infants and toddlers, as a surge of cases is outpacing supply. AstraZeneca CEO Pascal Soriot in an interview at the Reuters office in New York said the U.S. Centers for Disease Control and Prevention (CDC) had been asking for more of the antibody therapy that was co-developed with French drugmaker Sanofi.

AstraZeneca on Friday said it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus, which was approved in July to prevent the disease in infants and toddlers, as a surge of cases is outpacing supply. AstraZeneca CEO Pascal Soriot in an interview at the Reuters office in New York said the U.S. Centers for Disease Control and Prevention (CDC) had been asking for more of the antibody therapy that was co-developed with French drugmaker Sanofi.

Novavax reported revenue of $187 million for the quarter, down from $734.58 million a year ago, but above analysts' expectations of $158.5 million, according to LSEG data. "We've really optimized that U.S. grant opportunity, which was something that was uncertain at the beginning of the year," Novavax CEO John Jacobs said in an interview, adding that the government had shortened the timeline for being able to tap into those funds. The Maryland-based biotech has flagged concerns about its ability to remain in business and has been banking on cost cuts and commercial sales ...

COVID-19 vaccine maker Novavax on Thursday reported higher-than-expected revenue for the third quarter, boosted by U.S. government grants to help cover the expense of clinical trials. ...

By Patrick Wingrove and Bhanvi Satija (Reuters) -COVID-19 vaccine maker Novavax on Thursday beat market estimates for quarterly revenue, boosted by U.S.